EGFR-NSCLC Market: Current Analysis and Forecast (2023-2030)

EGFR-mutated non-small cell lung cancer is a subtype of lung cancer that occurs when there is a mutation in the epidermal growth factor receptor (EGFR) gene. This mutation causes the EGFR protein to become overactive, leading to the growth and spread of cancer cells. EGFR-mutated NSCLC is relatively rare, accounting for only about 10-15% of all NSCLC cases. Furthermore, the focus on early diagnosis and timely intervention, along with its collaborative research initiatives, has led to the identification of potential biomarkers and innovative drug candidates. Also, Women diagnosed with lung cancer in the UK are going to overtake the number of men found to have the disease this year for the first time, according to Cancer Research UK. Lung cancer cases in women are expected to be 27,332 in the UK, eclipsing the number of cases for men.

The EGFR-NSCLC market is expected to grow at a steady rate of around 6.7% owing to the increasing going research and development of targeted therapies specifically designed to inhibit EGFR mutations. Furthermore, The FDA's accelerated review processes for breakthrough treatments have provided a conducive environment for introducing innovative drugs to the market and rising lung cancer in the country is the major reason behind this growth. For instance, according to the American Cancer Society's estimates nearly 236,740 new cases of lung cancer and about 130,180 deaths from lung cancer in 2022.

Based on drug type, the market is segmented into erlotinib, afatinib, gefitinib, osimertinib, and dacomitinib. The erlotinib category is to witness a considerable during the forecast period. Erlotinib, a first-generation EGFR tyrosine kinase inhibitor (TKI), has played a pivotal role in driving the EGFR-NSCLC market. It inhibits the activity of EGFR, effectively slowing down cancer cell growth and spread. Despite the emergence of newer agents, erlotinib remains a key treatment option, particularly for patients with EGFR-mutated NSCLC who have developed resistance to other therapies. The drug's well-established efficacy and relatively favorable safety profile contribute to its continued significance in the market.

On the basis of distribution channel, the market is categorized into online and offline. Among these, online category held a significant share of the market in 2022. Online distribution channels enable patients to research treatment options, understand their condition, and connect with specialized healthcare professionals, regardless of geographical barriers. This virtual connectivity empowers patients and caregivers to make informed decisions and seek appropriate therapies, contributing to the expansion of the EGFR-NSCLC market.

For a better understanding of the market adoption of the EGFR-NSCLC industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the rising awareness about the role of EGFR mutations in non-small cell lung cancer (NSCLC) has prompted increased screenings and diagnostics across diverse populations. This surge in early detection has led to higher demand for targeted therapies, driving pharmaceutical companies to invest significantly in research and development. Furthermore, the region's expanding healthcare infrastructure, coupled with favorable government policies and collaborations with international research organizations, has opened avenues for innovation and accelerated drug approvals, propelling the EGFR-NSCLC market's growth.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; AstraZeneca; Pfizer Inc.; Novartis AG; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Genentech, Inc.; Astellas Pharma Inc.